Quick-Med Technologies has entered into a patent and technology license agreement with Viridis BioPharma, under which Viridis is expected to manufacture, market and sell gauze wound dressings in India that incorporate Quick-Med's proprietary Nimbus antimicrobial technology.

Quick-Med’s patented technology, Nimbus is a antimicrobial technology that has been custom designed for wound care and other medical applications. Nimbus received de Novo FDA clearance in 2009 and has been commercialised in traditional wound care applications.

J Ladd Greeno, CEO of Quick-Med, said: “Our license agreement with Viridis BioPharma is an important part of our growth strategy to expand the application of our Nimbus technology into additional applications as well as significant, global markets.

“The introduction of Nimbus in India is a milestone for Quick-Med, and reflects the quality and safety of our technology. India’s large population, increasing investments in health care and fast growing wound care business offers a major market for our technology.”

Dilip Mehta, CEO of Viridis BioPharma, said: “This low cost Advanced Wound Care product addresses unmet need of the population in this vital health care area.”